HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
1.870
-0.080 (-4.10%)
At close: Sep 18, 2026, 4:00 PM EDT
1.880
+0.010 (0.53%)
After-hours: Sep 18, 2026, 7:30 PM EDT
HCW Biologics Revenue
HCW Biologics had revenue of $135.57K in the quarter ending June 30, 2026, with 1,969.74% growth. This brings the company's revenue in the last twelve months to $6.72M, up 707.02% year-over-year. In the year 2025, HCW Biologics had annual revenue of $54.23K, down -97.89%.
Revenue (ttm)
$6.72M
Revenue Growth
+707.02%
P/S Ratio
0.51
Revenue / Employee
$192,034
Employees
35
Market Cap
3.43M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.23K | -2.51M | -97.89% |
| Dec 31, 2024 | 2.57M | -275.00K | -9.68% |
| Dec 31, 2023 | 2.84M | -3.88M | -57.72% |
| Dec 31, 2022 | 6.72M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PMGC Holdings | 2.58M |
| 60 Degrees Pharmaceuticals | 1.21M |
| GeoVax Labs | 852.28K |
| BioRestorative Therapies | 357.87K |
| Addex Therapeutics | 136.51K |
| VivoSim Labs | 112.00K |
| Jupiter Neurosciences | 64.69K |
| Alaunos Therapeutics | 3.00K |
HCWB News
- 10 days ago - HCW Biologics Proxy statement: Proxy filing - Filings
- 11 days ago - HCW Biologics enters exclusive HCW11-006 distribution pact with Akron Biotech - TheFly
- 11 days ago - HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells - GlobeNewsWire
- 11 days ago - HCW Biologics Proxy statement: Proxy filing - Filings
- 17 days ago - HCW Biologics receives patent allowance for alopecia areata drug - TheFly
- 17 days ago - HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - GlobeNewsWire
- 22 days ago - HCW Biologics Registration statement: Registration filing - Filings
- 25 days ago - HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells - GlobeNewsWire